REGN in the 13F filings
Regeneron Pharmaceuticals · CUSIP 75886F107
- Quarter end
- 31 Dec 2023
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 17 Jan 2024
- Managers listing it
- 35
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q3 2023 and Q4 2023; 25 listed it in both
- Shares listed
- 24,926,379
- combined, among listed positions
- Reported value
- $21.9bn
- combined, at the quarter end
Among the 93 comparable managers: 22 buyers (opened or added shares) and 14 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing REGN in Q4 2023
35 of 35 holders
Largest increases and reductions, by shares
Increases
- Fidelity (FMR LLC)existing position · 10,317,415 shares now+476,523
- Holocene Advisors LPexisting position · 360,480 shares now+182,727
- Renaissance Technologies LLCexisting position · 243,062 shares now+81,000
- Man Group PLCexisting position · 93,560 shares now+53,173
- AllianceBernstein LPexisting position · 744,217 shares now+51,959
Reductions
- T. Rowe Price Associates Incexisting position · 718,052 shares now-1,499,613
- Wellington Management Group LLPexisting position · 1,102,090 shares now-404,795
- Neuberger Berman Group LLCexisting position · 465,889 shares now-241,922
- Two Sigma Advisers LPexisting position · 12,900 shares now-230,000
- Acadian Asset Management LLCexisting position · 45,285 shares now-26,007
New positions and exits
New (6)
Exited (1)
- PDT Partners LLCwas $1.9m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 20 | $8.0bn | n.a. | n.a. |
| Q3 2013 | 19 | $10.8bn | n.a. | n.a. |
| Q4 2013 | 17 | $8.9bn | n.a. | n.a. |
| Q1 2014 | 18 | $8.8bn | n.a. | n.a. |
| Q2 2014 | 20 | $8.4bn | n.a. | n.a. |
| Q3 2014 | 22 | $10.7bn | n.a. | n.a. |
| Q4 2014 | 16 | $12.3bn | n.a. | n.a. |
| Q1 2015 | 18 | $13.2bn | n.a. | n.a. |
| Q2 2015 | 16 | $14.7bn | n.a. | n.a. |
| Q3 2015 | 21 | $12.9bn | n.a. | n.a. |
| Q4 2015 | 20 | $15.3bn | n.a. | n.a. |
| Q1 2016 | 24 | $11.3bn | n.a. | n.a. |
| Q2 2016 | 20 | $10.5bn | n.a. | n.a. |
| Q3 2016 | 18 | $12.0bn | n.a. | n.a. |
| Q4 2016 | 22 | $10.4bn | n.a. | n.a. |
| Q1 2017 | 18 | $10.3bn | n.a. | n.a. |
| Q2 2017 | 23 | $13.6bn | n.a. | n.a. |
| Q3 2017 | 21 | $11.6bn | n.a. | n.a. |
| Q4 2017 | 27 | $9.4bn | n.a. | n.a. |
| Q1 2018 | 27 | $8.5bn | n.a. | n.a. |
| Q2 2018 | 24 | $9.2bn | n.a. | n.a. |
| Q3 2018 | 27 | $10.8bn | n.a. | n.a. |
| Q4 2018 | 28 | $9.9bn | n.a. | n.a. |
| Q1 2019 | 28 | $10.4bn | n.a. | n.a. |
| Q2 2019 | 29 | $8.3bn | n.a. | n.a. |
| Q3 2019 | 24 | $7.1bn | n.a. | n.a. |
| Q4 2019 | 18 | $9.0bn | n.a. | n.a. |
| Q1 2020 | 27 | $13.0bn | n.a. | n.a. |
| Q2 2020 | 23 | $19.8bn | n.a. | n.a. |
| Q3 2020 | 24 | $17.4bn | n.a. | n.a. |
| Q4 2020 | 26 | $15.2bn | n.a. | n.a. |
| Q1 2021 | 22 | $13.7bn | n.a. | n.a. |
| Q2 2021 | 27 | $15.3bn | n.a. | n.a. |
| Q3 2021 | 26 | $15.5bn | n.a. | n.a. |
| Q4 2021 | 28 | $16.3bn | n.a. | n.a. |
| Q1 2022 | 25 | $19.2bn | n.a. | n.a. |
| Q2 2022 | 26 | $16.5bn | n.a. | n.a. |
| Q3 2022 | 24 | $19.0bn | n.a. | n.a. |
| Q4 2022 | 30 | $20.2bn | n.a. | n.a. |
| Q1 2023 | 32 | $22.3bn | n.a. | n.a. |
| Q2 2023 | 28 | $18.8bn | n.a. | n.a. |
| Q3 2023 | 26 | $21.1bn | n.a. | n.a. |
| Q4 2023 | 35 | $21.9bn | 22 | 14 |
| Q1 2024 | 28 | $23.6bn | 12 | 20 |
| Q2 2024 | 28 | $25.6bn | 15 | 15 |
| Q3 2024 | 31 | $25.0bn | 17 | 15 |
| Q4 2024 | 27 | $13.8bn | 17 | 12 |
| Q1 2025 | 29 | $12.2bn | 20 | 10 |
| Q2 2025 | 32 | $9.3bn | 24 | 10 |
| Q3 2025 | 33 | $10.1bn | 22 | 12 |
| Q4 2025 | 33 | $16.3bn | 20 | 23 |
| Q1 2026 | 24 | $15.2bn | 14 | 26 |
| Q2 2026 | 22 | $10.6bn | 24 | 15 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
REGN and LLY →REGN and JNJ →REGN and VRTX →Choose a stock to compare with REGN →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own REGN, latest filings →Back to the 13F Explorer →